Dr. Wilky on Ongoing Trial of Pembrolizumab and Axitinib in Sarcoma

Breelyn Wilky, MD
Published: Tuesday, Mar 21, 2017



Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses the status of a phase II trial investigating concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in patients with advanced alveolar soft part sarcoma and other soft tissue sarcomas.

This is a clinical trial that is currently in progress, Wilky explains. Therefore, there are not yet any published findings. However, she adds, there are 13 of the 30 planned patients enrolled, several of which have alveolar soft part sarcoma, but also other histologies in soft tissue sarcoma.

She explains that there have not been any prohibitive, severe toxicities from the combination. It is hopeful that preliminary results will be ready to be presented at the 2017 ASCO Annual Meeting.
 


Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses the status of a phase II trial investigating concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in patients with advanced alveolar soft part sarcoma and other soft tissue sarcomas.

This is a clinical trial that is currently in progress, Wilky explains. Therefore, there are not yet any published findings. However, she adds, there are 13 of the 30 planned patients enrolled, several of which have alveolar soft part sarcoma, but also other histologies in soft tissue sarcoma.

She explains that there have not been any prohibitive, severe toxicities from the combination. It is hopeful that preliminary results will be ready to be presented at the 2017 ASCO Annual Meeting.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x